Blue Jet Healthcare Limited
477.05
INR
-10.65
(-2.18%)
ISIN
INE0KBH01020
Return %
Stock
S&P 500
1Y
-26.72
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Shiven Akshay Arora
- Full Time Employees
- 581
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Bhumiraj Costarica, Plot No. 1 & 2 Thane MA India 400705
- IPO Date
- Nov 6, 2023
- Website
- bluejethealthcare.com
- Similar Companies
- Business
- Blue Jet Healthcare Limited is an India-based pharmaceutical company specializing in the manufacturing and sale of contrast media intermediates, high-intensity sweeteners, pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). Founded in 1968 and headquartered in Mumbai, the company serves innovator pharmaceutical firms, multinational generic pharmaceutical companies, research laboratories, and FMCG sectors globally. Its main product categories include contrast media intermediates used to enhance diagnostic imaging in X-rays, CT scans, and MRIs; pharmaceutical intermediates and APIs targeting niche and complex molecules for anti-infectives, CNS drugs, cardiovascular and gastrointestinal treatments; and high-intensity sweeteners, primarily saccharin and related salts, for healthcare and food industries. Blue Jet Healthcare also provides contract development and manufacturing services (CDMO) with specialized chemistry capabilities. Recent major developments include a strategic greenfield expansion project in Andhra Pradesh with over ₹1,000 crore investment to augment global CDMO capacities and deepen engagement with international customers, reflecting a significant push to scale operations and technological capabilities. The company, which evolved from Jet Chemicals Pvt Ltd, has changed its corporate status and name multiple times since incorporation, most recently becoming Blue Jet Healthcare Limited in 2022. It operates internationally with regulatory approvals including US FDA and ISO certifications, positioning itself as a science-led partner in pharmaceutical ingredient development and manufacturing across several countries including India, Norway, France, the United States, Italy, and Sweden. The expansion and diversification into CDMO services mark a strategic shift for Blue Jet Healthcare towards building a robust global manufacturing footprint in advanced pharmaceutical intermediates and APIs.